Abstract
Hepatocellular carcinoma (HCC) is a lethal malignancy worldwide with frequent intrahepatic and distant metastasis. Elucidating the underlying molecular mechanism that modulates HCC progression is critical for exploring novel therapeutic strategies. Serine/Threonine Kinase 17B (STK17B) is upregulated in HCC tissues, but its role in HCC progression remains elusive. In the present studies, we reported that STK17B had a critical role in HCC progression. STK17B was significantly upregulated in HCC cell lines and specimens, and patients with ectopic STK17B expression characterized with poor clinicopathological features. In vitro and in vivo assay demonstrated that inhibition of STK17B markedly inhibits HCC tumorigenesis and metastasis, while STK17B overexpression promoted these processes. Furthermore, we found that STK17B promoted EMT process via activating AKT/GSK-3β/Snail signal pathway, and miR-455-3p was identified as the upstream regulator of STK17B. Combination of high level of STK17B and low level of miR-455-3p predicted poor prognosis with higher accuracy for HCC patients. In conclusion, our research demonstrated that STK17B promotes HCC progression, induces EMT process via activating AKT/GSK-3β/Snail signal and predicts poor prognosis in HCC.
Similar content being viewed by others
Introduction
Hepatocellular carcinoma (HCC), the fifth most common malignancy globally, causes almost 0.7 million deaths annually, and HCC has become the third leading cause of cancer-related mortality1. Currently, HCC is still treated most effectively through surgical resection and liver transplantation although multiple novel therapeutic strategies have been developed. Furthermore, most HCC patients are diagnosed at an advanced stage, which precludes surgery as a feasible treatment option. Recurrence and metastasis after various treatments are the most intractable obstacles hindering a marked enhancement of the overall survival rate among HCC patients2. Over the past few decades, numerous basic research have been conducted on HCC, however, further investigation is still necessary to elucidate the mechanism underlying HCC carcinogenesis and thus develop an optimal therapeutic strategy for HCC.
Serine/threonine kinase 17B (STK17B), whose gene is located on chromosome 2 (2q32.3), was first reported by Sanjo et al. in 19983. Previous findings have indicated that STK17B expression is highly enriched in B and T cells suggesting the possible involvement of this gene in immunological processes4. Therefore, STK17B has been identified as a promising therapeutic target for type 1 diabetes, multiple sclerosis, and graft rejection5. There are also some reports demonstrated that STK17B was related to apoptosis in various cell types, such as islet β-cells and acute myeloid leukemia cells6,7, but it is still controversial and its ability to regulate apoptosis seems to depend on the cellular context8,9. Some researches revealed that STK17B was deregulated in some cancers and have important role in cancer progression. Yang et al.10 found that endogenous STK17B expression was elevated in basal-like and HER2-enriched breast cancer, and loss of STK17B suppressed tumorigenesis and tumor growth in xenograft model. Hartmann et al.11 reported that STK17B was expressed at high levels in cutaneous T-cell lymphomas, and Tomimaru et al.12 showed that STK17B was overexpressed in HCC tissue. These findings indicated that STK17B might promote tumor progression. However, a consensus of STK17B’s function in cancer was not reached in previous studies, because STK17B may act as a tumor suppressor in leukemia and colorectal cancer7,13. Thus, the information indicated that STK17B may have dual functions in tumor progression, and we suspected that STK17B functions in a disease-dependent or cellular-dependent manner.
Epithelial–mesenchymal transition (EMT) is critical in the progression of metastasis in multiple cancers. In this process epithelial cells are induced to gain mesenchymal characteristic14. Various signaling pathways that were abnormally activated or inactivated in tumor progression were responsible for regulating EMT process, such as TGF-β/Smad, JAK/Stat3, and Wnt/β-catenin15,10,11,12,13, and there was also a study demonstrated its upregulation in HCC. However, the exact role of STK17B and its related mechanism still remained elusive.
In this study, we investigated the role of STK17B in HCC progression, particularly its effects on proliferation, metastasis, and invasion. We obtained evidence that STK17B was upregulated in HCC tissues, and we determined that the upregulation was associated with tumor size, TNM stage, and venous invasion by analyzing the clinicopathological features. In agreement with the clinicopathological features, our results suggested that STK17B silence suppressed tumorigenesis and caused cell cycle arrest at G1 phase in HCC. In addition, the results derived from in vitro cell migration, invasion assay, and in vivo metastasis assay confirmed that STK17B promote metastasis in HCC. Investigation of the mechanism through which STK17B promoted metastasis revealed that STK17B overexpression promoted the EMT process. We found STK17B can induce HCC cell to gain mesenchymal feature. Meanwhile, epithelial maker (E-cadherin) was suppressed while mesenchymal makers (N-cadherin and Vimentin) were increased by STK17B. To clarify the regulatory interaction between STK17B and EMT, several transcription factors which were upstream regulators of EMT and EMT-related signal pathways were measured. Finally, Snail and AKT pathway were found to be positively related to STK17B. Previous studies have revealed that AKT/GSK-3β/Snail pathway is widely accepted in modulating EMT20,21, therefore we hypothesized that there might be a relationship between STK17B and this pathway. Our western blotting results indicated that STK17B expression can result in elevation of phosphorylated AKT, and thereby inhibition of GSK-3β and upregulation of Snail. Subsequently, activation of this pathway modulates E-cadherin, N-cadherin, and vimentin expression and thereby induces EMT.
Various miRNAs have been demonstrated to be aberrantly expressed in malignant tumors, including HCC31, and almost one-third of all human genes are regulated by miRNAs. Here, we identified miR-455-3p, which has been reported to be associated with HCC32,33, as an upstream suppressor of STK17B by performing bioinformatics analysis and luciferase reporter assy. Accordingly, miR-455-3p attenuated the function of STK17B, and the results of qRT-PCR analysis of HCC specimens confirmed a negative correlation between miR-455-3p and STK17B expression. Clinicopathological analysis also confirmed downregulation of miR-455-3p predicts poor clinical outcomes. Moreover, we demonstrated that a combination of high STK17B expression and low miR-455-3p expression predicts a poor prognosis in HCC patients.
Taken together, the present study identified that STK17B is upregulated in HCC tissues and cell lines, and may predicts poor clinical outcomes. Moreover, STK17B might function as a regulator of HCC carcinogenesis and metastasis. Interestingly, STK17B, miR-455-3p, and the AKT/GSK-3β/Snail pathway might operate in combination in regulating the EMT process—and thereby metastasis—in HCC.
Materials and methods
Cell lines and cell culture
An immortalized normal liver cell line (L02) and several HCC cell lines (SMMC7721, Huh7, HCCLM3, HepG2, Sk-Hep-1, and Hep3B) were purchased from Cell Bank of Type Culture Collection of the Chinese Academy of Sciences, Shanghai Institute of Cell Biology, Chinese Academy of Sciences. All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) at 37 °C in a 5% CO2 incubator.
Patients and clinical samples
HCC tissues and corresponding adjacent non-tumorous liver tissues (ANLTs) were collected from patients on whom hepatic resection was performed at the First Affiliated Hospital of Harbin Medical University between January 2008 and May 2013. Informed consent was obtained from all patients, and the research application for human subjects was approved by the Research Ethics Committee of the First Affiliated Hospital of Harbin Medical University. Every HCC diagnosis was based on World Health Organization criteria. Follow-up data were regularly collected from patients after hepatic resection to access the overall rate of and to monitor the cancer metastasis and recurrence. The patents’ clinicopathological data are presented in Supplementary Table 2.
Lentivirus, oligonucleotides, and reagents
Lentiviral vectors for STK17B gene overexpression (Lv-STK17B) and downregulation (Lv-shSTK17B) were constructed by and purchased from GeneChem Corporation (Shanghai, China); the empty vector (Lv-NC) was used as a negative control. Virus for interfering Snail was also bought from GeneChem Corporation. A lentiviral vector encoding the firefly luciferase gene was constructed by and purchased from GeneChem Corporation. All other lentiviral vectors were designed by and purchased from GeneChem Technologies. Oligonucleotides for miR-455-3p overexpression (mimics) and knockdown (inhibitor), and the corresponding negative-control (NC) oligonucleotide, were purchased from RiboBio Corporation (Guangzhou, China). Information on all the primary antibodies used here is provided in Supplementary Table 3. Detailed information regarding the primers and probes used for quantitative real-time PCR (qRT-PCR) is listed in Supplementary Table 4.
Immunohistochemical (IHC) analysis
Formalin-fixed and paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated in a gradient ethanol series, after which antigen retrieval was performed in an antigen-unmasking solution (citrate-based). After blocking with normal bovine serum, the sections were incubated with primary antibodies at optimal dilutions (overnight, 4 °C) and then with biotinylated secondary antibodies (Vector Laboratories, Burlingame, CA, USA). Lastly, the sections were stained with diaminobenzidine (DAB Kit; Vector Laboratories) and counterstained with hematoxylin (Sigma, St. Louis, MO, USA) to visualize the immunoreaction product. Staining density was evaluated using an IHC method described previously34.
Cell-viability and colony-formation assays
Transfected cells were seeded in 96-well plates (1 × 103 cells per well) and incubated overnight at 37 °C under 5% CO2 to allow attachment. Cell viability at various time points was measured using Cell Counting Kit-8 (CCK-8) assays (CK04-01; Do**do Molecular Technologies, Inc., Japan). The primary medium in the wells was replaced with 100 μl of complete medium supplemented with 10 μl of CCK-8 reagent, and after incubating at 37 °C under 5% CO2 for 4 h, 450-nm absorbance was measured. Six replicates were used for each experiment.
For colony-formation assays, transfected cells were seeded in 6-well plates at 300–500 cells per well and incubated at 37 °C under 5% CO2 for 14 days. Subsequently, the cells were fixed by adding 4% (w/v) paraformaldehyde into each well and incubating for 10 min, after which staining was performed with 0.5% crystal violet to visualize colonies. Images were captured using a Nikon camera.
Wound-healing assay
Cells were seeded in 6-well plates and cultured at 37 °C under 5% CO2 for 24 h to ensure that the cells grew to confluence, after which a wound was scratched in each well by using a 10-μl pipette tip. Cells were washed thrice with phosphate-buffered saline (PBS) and then 2 ml of complete culture medium was added into each well. Wound closure was monitored at 0, 24, and 36 h, and representative scratch lines were photographed by using an inverted microscope equipped with a Nikon camera. Three replicated wells were established for each condition.
Transwell assay
In vitro invasion capability was measured using 24-well BioCoat cell-culture inserts (BD Biosciences, NJ, USA) pre-coated or not pre-coated with Matrigel on the polyethylene terephthalate membrane. In the upper compartment of the Transwell chambers, we seeded 2 × 104 cells suspended in 500 μl of serum-free medium, and we filled the lower compartment with complete medium. After incubation at 37 °C under 5% CO2 for 24–48 h, some of the cells had migrated through the porous membrane, whereas the non-migrating cells remained on the upper surface of the filter. The chamber was now immersed in methanol for 10 min to fix the cells, and then scrubbed gently to remove the non-metastatic cells. The migrated cells were stained with 0.5% crystal violet for 10 min and counted under a light microscope. Each experiment was independently performed thrice.
Western blotting
Harvested cells were lysed in RIPA buffer supplemented with protease and phosphatase inhibitors to prepare total protein samples. After measuring protein concentrations, the samples were separated using SDS-PAGE and then electro-transferred onto polyvinylidene fluoride (PVDF) membranes (Invitrogen, Eugene, OR, USA). The PVDF membranes were blocked in 5% skim milk for 1 h at room temperature, incubated overnight at 4 °C with primary antibodies at optimal dilution, washed with PBST (PBS containing 0.1% Tween-20), and incubated with HRP-conjugated secondary antibodies. Lastly, protein expression was visualized by detecting the immunoreactive bands on the membranes by using an enhanced chemiluminescence kit (Pierce, Rockford, IL, USA).
Real-time PCR
Total RNA was extracted from cultured cells by using an RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions, and the RNA was reverse-transcribed into cDNA by using a High Capacity Reverse Transcription Kit (Applied Biosystems, Grand Island, NY). Real-time PCR was conducted using Power SYBR Green PCR Master Mix (Life Technologies, USA), on an ABIPRISM 7900HT instrument (Applied Biosystems, Grand Island, NY), and mRNA expression levels were normalized relative to the GAPDH mRNA level. For microRNA (miRNA) analyses, RT-PCR and real-time PCR were performed using, respectively, a TaqMan® MicroRNA Reverse Transcription Kit and TaqMan® Universal Master Mix II no UNG (both from Applied Biosystems, Grand Island, NY). The miRNA expression level was normalized relative to the U6 level.
Cell cycle analysis
Cells (4 × 105) were fixed in 70% ethanol for 1 h at 4 °C. Then the cells were washed twice with PBS followed by adding 10 mg/ml RNase A. After that propidium iodide was added at a final concentration of 0.05 mg/ml, the samples were incubated at 4 °C for 30 min in a dark environment. Finally, samples were analyzed by flow cytometry (Beckman Coulter FC 500).
Immunofluorescence (IF) assay
Cultured cells were seeded on coverslips in advance and fixed with 4% (w/v) paraformaldehyde for 10 min. Subsequently, the cells were permeabilized for 20 min in 0.1% (v/v) Triton X-100 at room temperature, incubated with primary antibodies overnight at 4 °C and then with fluorescent secondary antibodies (Invitrogen) for 1 h at room temperature, and washed thrice with PBS. Lastly, the cells counterstained with DAPI (Vector Laboratories) and then images were captured.
Luciferase assay
Luciferase activity was accessed using a luciferase assay kit (Promega, Madison, WI, USA). Cells were seeded in 24-well plates and incubated for 24 h, and then specific plasmids were cotransfected with 1 ng of pRL-TK Renilla luciferase plasmid into the cells by using Lipofectamine 2000 (Invitrogen). At 48 h after transfection, the Dual-Luciferase Reporter Assay System (Promega) was used to measure luciferase activity according to the manufacturer’s instructions.
Animal studies
Male BALB/c athymic nude mice (4–6 weeks old) were purchased from the experimental animal center of Shanghai Institute for Biological Sciences. The experimental protocol was reviewed and approved by the Committee on the Use of Live Animals in Teaching and Research of the Harbin Medical University, Harbin, China. All animals were housed under standard pathogen-free conditions. To establish subcutaneous xenograft tumors, 2 × 106 cells suspended in 100 μl of PBS were injected into the flank of mice. Tumor size was monitored weekly by using Vernier calipers until all animal were killed at the 6th week. Tumor volume was calculated as previously reported35.
Subcutaneous xenograft tumors can be visualized after 1 week. Tumors were resected and diced into 1 mm3 cubes, which were then implanted into the left lobe of the liver in mice. Subsequently, tumor size was monitored by measuring the bioluminescence signal every week until all mice were killed for collecting tumor tissues at the 6th week.
The lung metastasis model was established to access in vivo metastasis: 3 × 106 cells were injected into nude mice through the tail vein, and 6 weeks later, bioluminescence was measured using a Berthold NIGHTOWL LB983 imaging machine. After the imaging, all mice were killed, and the lung was resected for counting metastatic nodules and for hematoxylin–eosin (H&E) staining.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 software (SPSS, Chicago, IL, USA) and the GraphPad Prism software package (v. 6.01, San Diego, CA, USA). All data are presented as means ± SD. Variance between two groups was analyzed using unpaired Student’s t tests. P < 0.05 was considered statistically significant.
Disclaimer
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. & Forman, D. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).
Pang, R. W., Joh, J. W., Johnson, P. J., Monden, M., Pawlik, T. M. & Poon, R. T. Biology of hepatocellular carcinoma. Ann. Surg. Oncol. 15, 962–971 (2008).
Sanjo, H., Kawai, T. & Akira, S. DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. J. Biol. Chem. 273, 29066–29071 (1998).
McGargill, M. A., Wen, B. G., Walsh, C. & MHedrick, S. M. A deficiency in Drak2 results in a T cell hypersensitivity and an unexpected resistance to autoimmunity. Immunity 21, 781–791 (2004).
Edwards, B. A. et al. Drak2 is not required for tumor surveillance and suppression. Int Immunol. 27, 161–166 (2015).
Wang, S. et al. Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet beta-cells from apoptosis. Eur. J. Med Chem. 130, 195–208 (2017).
Ye, P., Zhao, L. & Gonda, T. J. The MYB oncogene can suppress apoptosis in acute myeloid leukemia cells by transcriptional repression of DRAK2 expression. Leuk. Res 37, 595–601 (2013).
Kuwahara, H., Nakamura, N. & Kanazawa, H. Nuclear localization of the serine/threonine kinase DRAK2 is involved in UV-induced apoptosis. Biol. Pharm. Bull. 29, 225–233 (2006).
Jung, M. E. et al. Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening. Bioorg. Med Chem. Lett. 26, 2719–2723 (2016).
Yang, K. M. et al. DRAK2 participates in a negative feedback loop to control TGF-beta/Smads signaling by binding to type I TGF-beta receptor. Cell Rep. 2, 1286–1299 (2012).
Hartmann, T. B. et al. Identification of selectively expressed genes and antigens in CTCL. Exp. Dermatol. 17, 324–334 (2008).
Tomimaru, Y., Koga, H., Yano, H., de la Monte, S., Wands, J. R. & Kim, M. Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int 33, 1100–1112 (2013).
Doherty, G. A. et al. Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer. Br. J. Cancer 101, 483–491 (2009).
Acloque, H., Adams, M. S., Fishwick, K., Bronner-Fraser, M. & Nieto, M. A. Epithelial–mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest 119, 1438–1449 (2009).
Wu, Y. et al. Calreticulin regulates TGF-beta1-induced epithelial–mesenchymal transition through modulating Smad signaling and calcium signaling. Int J. Biochem Cell Biol. 90, 103–113 (2017).
**ao, J. et al. IL-6 promotes epithelial-to-mesenchymal transition of human peritoneal mesothelial cells possibly through the JAK2/STAT3 signaling pathway. Am. J. Physiol. Ren. Physiol. 313, F310–F318 (2017).
Niu, H. et al. Silencing PPA1 inhibits human epithelial ovarian cancer metastasis by suppressing the Wnt/beta-catenin signaling pathway. Oncotarget 8, 76266–76278 (2017).
Chang, R. M., Yang, H., Fang, F., Xu, J. F. & Yang, L. Y. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology 60, 1251–1263 (2014).
Wang, L. et al. C-type lectin-like receptor 2 suppresses AKT signaling and invasive activities of gastric cancer cells by blocking expression of phosphoinositide 3-kinase subunits. Gastroenterology 150, 1183–1195 e1116 (2016).
Liu, L. et al. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial–mesenchymal transition by way of Akt/GSK-3beta/Snail signaling. Hepatology 59, 531–543 (2014).
Bellacosa, A. & Larue, L. in Cancer Genome and Tumor Microenvironment (ed Thomas-Tikhonenko, A.) 11–32 (Springer, New York, 2010).
Zhang, Y. et al. MiR-424-5p reversed epithelial–mesenchymal transition of anchorage-independent HCC cells by directly targeting ICAT and suppressed HCC progression. Sci. Rep. 4, 6248 (2014).
Fang, J. H. et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 54, 1729–1740 (2011).
Budhu, A. et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47, 897–907 (2008).
Fornari, F. et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27, 5651–5661 (2008).
Chang, Y. et al. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 143, 177–187 e178 (2012).
Zhang, P. et al. MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer. Br. J. Cancer 117, 525–534 (2017).
Shariat, S. F. et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J. Urol. 183, 68–75 (2010).
Li, J. et al. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget 6, 9551–9563 (2015).
Pei, T. et al. YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget 6, 17206–17220 (2015).
Murakami, Y. et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537–2545 (2006).
Cheng, L. et al. Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs. Oncotarget 7, 61199–61214 (2016).
Qin, L., Zhang, Y., Lin, J., Shentu, Y. & **e, X. MicroRNA-455 regulates migration and invasion of human hepatocellular carcinoma by targeting Runx2. Oncol. Rep. 36, 3325–3332 (2016).
Liang, Y. et al. Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinoma. PLoS ONE 6, e23908 (2011).
Wang, J. et al. N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway. Hepatology 64, 1606–1622 (2016).
Acknowledgements
This study was supported by National Key Program for Science and Technology Research and Development (Grant Nos. 2016YFC0106503, 2016YFC0106500, 2016YFC0905902), Program for Innovative Research Team (in Science and Technology) in Higher Educational Institutions of Heilongjiang Province (Grant No. 2009td06), Changjiang Scholars and Innovative Research Team in University (Grant No. IRT1122), the National Natural Scientific Foundation of China (Nos. 81301807, 81302060, 81602058, 81773194), Innovative Research Program for Graduate of Harbin Medical University (Grant Nos. YJSCX2015-17HYD, YJSCX201434HYD), Foundation of the First Affiliated Hospital of Harbin Medical University (Grant No. 2013LX04), China Postdoctoral Science Foundation (Grant Nos. 2015T80368 and 2014M560270), Heilongjiang Postdoctoral Science Foundation (Grant Nos. LBH-Z14173 and LBH-TZ0618), and Foundation of Harbin Science and Technology Bureau (Grant No. RC2014QN004152).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lan, Y., Han, J., Wang, Y. et al. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma. Cell Death Dis 9, 236 (2018). https://doi.org/10.1038/s41419-018-0262-1
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-018-0262-1
- Springer Nature Limited
This article is cited by
-
Constructing lncRNA-miRNA-mRNA networks specific to individual cancer patients and finding prognostic biomarkers
BMC Genomic Data (2024)
-
The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1
Journal of Experimental & Clinical Cancer Research (2022)
-
Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia
Cell & Bioscience (2022)
-
Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway
Journal of Experimental & Clinical Cancer Research (2021)
-
Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1
Molecular Cancer (2021)